ByTrending Posts
Is Novartis Bolstering Its Radioligand Oncology Pipeline at…
Basel / San Francisco | January 2026 Novartis has expanded its precision oncology strategy with a global license and…
Is Pfizer’s $10 Billion Metsera Acquisition at JPM2026…
San Francisco / New York | January 2026 Pfizer has made a decisive strategic move to expand its…
Is Amgen Bolstering Its Oncology Pipeline at JPM…
Thousand Oaks, U.S. | January 2026 Amgen has expanded its oncology growth strategy with the acquisition of Dark…
Is AstraZeneca’s Acquisition of Modella AI at JPM…
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is AbbVie’s $5.6 Billion RemeGen Licensing Deal at…
Chicago, U.S. | January 2026 AbbVie has reinforced its commitment to externally sourced innovation with a major oncology…
Is the $1 Billion Lilly–NVIDIA Alliance at JPM26…
San Francisco | January 12, 2026 The 44th Annual J.P. Morgan Healthcare Conference (JPM26) opened with a defining…
Lantern Pharma Secures FDA Orphan Drug Designation for…
Dallas, U.S. | January 20, 2026 Lantern Pharma has strengthened its precision oncology pipeline after the U.S. Food…
Can Amgen’s 2025 Approvals and Launches Strengthen Its…
Global | January 2026 — Amgen Inc. achieved key milestones in 2025, marked by multiple regulatory approvals, label…
Can GSK’s 2025 Approvals and Launches Strengthen Its…
Global | January 2026 — GlaxoSmithKline PLC (GSK) achieved key milestones in 2025, with multiple regulatory approvals, product…
Trending Posts
Latest Stories
BioNextAI Media Report: Keytruda’s Ovarian Cancer Combo Triumph—28% Survival Boost Lifts Merck Stock 4% Amid Patent Shadow
Published by BioNextAI Media – Merck’s KEYTRUDA (pembrolizumab) delivered compelling Phase 3 data from combination regimens…
BioNextAI Media Report: Merck’s Gardasil Cuts—$200M Savings, 150 Layoffs Amid 5-10% Demand Drop
Published by BioNextAI Media – In a calculated response to softening markets, Merck is halting production…
Merck’s Bold Pivot: Can Dividing Oncology from the Rest Save Keytruda’s Legacy?
Merck’s audacious restructuring of its pharmaceutical operations into standalone oncology and non-oncology divisions isn’t mere…
Lilly’s $2.4B Bet on In Vivo CAR-T: Acquiring Orna Therapeutics to Revolutionize Autoimmune Treatments
Eli Lilly and Company revealed plans in early February 2026 to acquire Orna Therapeutics, a…
Gallery
